All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On 4 June 2018, the results from the phase I/II REVLIRIT CLL-5 AGMT study were published in Annals of Hematology by Alexander Egle, Department of Internal Medicine III with Hematology and Medical Oncology, Oncologic center, Paracelsus Medical University Salzburg, Austria, and colleagues. This study evaluated the use of escalating doses of lenalidomide with fludarabine and rituximab (FR) followed by lenalidomide and rituximab maintenance in patients with previously untreated chronic lymphocytic leukemia (CLL).
The authors concluded that lenalidomide with FR was effective at induction responses and maintenance with lenalidomide and rituximab demonstrated long PFS with patients with previously untreated CLL. The authors also noted that due to recent efficacious novel treatments, they doubted the role of lenalidomide chemoimmunotherapy combinations in the treatment of previously untreated CLL.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox